Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells

Immunology Letters

Volumn 123, Issue 2, 2009, Pages 155-159

  Reich, Michael ^a   Wieczerzak, Ewa ^b   Jankowska, Elzbieta ^b   Palesch, David ^a   Boehm, Bernhard O ^a   Burster, Timo ^a  

^a Division of Endocrinology and Diabetes   (Germany)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Antigen presentation processing; Cathepsin B; MHC

Indexed keywords

CATHEPSIN B; CATHEPSIN B INHIBITOR; CYSTEINE; GAMMA INTERFERON; INTERLEUKIN 17; TETANUS TOXIN; TETANUS TOXIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL SPECIFICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; DRUG PENETRATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CATHEPSIN B; CELL MEMBRANE PERMEABILITY; CYSTEINE PROTEINASE INHIBITORS; DENDRITIC CELLS; DIPEPTIDES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TETANUS TOXIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349154990     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.03.006     Document Type: Article

References (22)

1. Zavasnik-Bergant T., and Turk B. Cysteine cathepsins in the immune response. Tissue Antigens 67 (2006) 349-355
2. Rudensky A., and Beers C. Lysosomal cysteine proteases and antigen presentation. Ernst Schering Res Found Workshop (2006) 81-95
3. Watts C., Matthews S.P., Mazzeo D., Manoury B., and Moss C.X. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol Rev 207 (2005) 218-228
4. Stoeckle C., Sommandas V., Adamopoulou E., Belisle K., Schiekofer S., Melms A., et al. Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cell Immunol 255 (2009) 41-45
5. Bennett K., Levine T., Ellis J.S., Peanasky R.J., Samloff I.M., Kay J., et al. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur J Immunol 22 (1992) 1519-1524
6. Nishioku T., Hashimoto K., Yamashita K., Liou S.Y., Kagamiishi Y., Maegawa H., et al. Involvement of cathepsin E in exogenous antigen processing in primary cultured murine microglia. J Biol Chem 277 (2002) 4816-4822
7. Chain B.M., Free P., Medd P., Swetman C., Tabor A.B., and Terrazzini N. The expression and function of cathepsin E in dendritic cells. J Immunol 174 (2005) 1791-1800
8. Villadangos J.A., Riese R.J., Peters C., Chapman H.A., and Ploegh H.L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 186 (1997) 549-560
9. Costantino C.M., Hang H.C., Kent S.C., Hafler D.A., and Ploegh H.L. Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation. J Immunol 180 (2008) 2876-2885
10. Zaidi N., Burster T., Sommandas V., Herrmann T., Boehm B.O., Driessen C., et al. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochem Biophys Res Commun 364 (2007) 243-249
11. Burster T., Reich M., Zaidi N., Voelter W., Boehm B.O., and Kalbacher H. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells. Biochem Biophys Res Commun 377 (2008) 1299-1303
12. Buttle D.J., Murata M., Knight C.G., and Barrett A.J. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys 299 (1992) 377-380
13. Montaser M., Lalmanach G., and Mach L. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol Chem 383 (2002) 1305-1308
14. Wieczerzak E., Rodziewicz-Motowidlo S., Jankowska E., Gieldon A., and Ciarkowski J. An enormously active and selective azapeptide inhibitor of cathepsin B. J Pept Sci 13 (2007) 536-543
15. Jacquier-Sarlin M.R., Gabert F.M., Villiers M.B., and Colomb M.G. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84 (1995) 164-170
16. Greenbaum D., Medzihradszky K.F., Burlingame A., and Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 7 (2000) 569-581
17. Burster T., Beck A., Tolosa E., Marin-Esteban V., Rotzschke O., Falk K., et al. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. J Immunol 172 (2004) 5495-5503
18. Burster T., Beck A., Tolosa E., Schnorrer P., Weissert R., Reich M., et al. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. J Immunol 175 (2005) 5940-5949
19. Burster T., Giffon T., Dahl M.E., Bjorck P., Bogyo M., Weber E., et al. Influenza A virus elevates active cathepsin B in primary murine DC. Int Immunol 19 (2007) 645-655
20. + T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol 161 (1998) 2120-2127
21. Lawrence C.P., Kadioglu A., Yang A.L., Coward W.R., and Chow S.C. The cathepsin B inhibitor, z-FA-FMK, inhibits human T cell proliferation in vitro and modulates host response to pneumococcal infection in vivo. J Immunol 177 (2006) 3827-3836
22. Bogyo M., Verhelst S., Bellingard-Dubouchaud V., Toba S., and Greenbaum D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol 7 (2000) 27-38